# Dan 1 – Informacije o srečanju na temo multiplega mieloma

|  |  |  |
| --- | --- | --- |
|  | **EN** | **Lokalni jezik** |
|  | **Date: 12.04.2019**  **Specialty: Hematology**  **Language: English**  **Translation languages: None**  **Start: 12.04.2019 15:00 CEST**  **Duration: 180 minutes total (breaks excluded)** | **Datum: 12. 4. 2019**  **Področje: hematologija**  **Jezik: angleščina**  **Prevod v jezike: brez**  **Začetek: 12. 4. 2019 15:00 CEST**  **Trajanje: skupno 180 minut (brez premorov)** |
| **Session title (the shorter, the better)** | New therapeutic trends in Multiple Myeloma treatment | Novi terapevtski trendi pri zdravljenju multiplega mieloma |
| **Short description (max. 250 characters with spaces)** | We would like to invite you to our upcoming, live and interactive medical educational forum, taking place on Friday, 12 April 2019, broadcast from Budapest. This session will discuss optimal approach and recent treatment advances of Multiple Myeloma. | Vabimo vas k udeležbi na prihajajočem interaktivnem medicinskem izobraževalnem forumu, katerega prenos bo v živo potekal v petek, 12. aprila 2019, iz Budimpešte. Na srečanju se bo razpravljalo o optimalnih pristopih in zadnjih dosežkih na področju zdravljenja multiplega mieloma. |
| **Description (min. 300 characters with spaces)** | Medical education forum focused on optimal approach to treatment of Multiple Myeloma. Discussion will cover recent updates of international scientific results of MM treatment, allow experience exchange and best practise sharing in the field of therapy of MM patients with innovative agents.  **AGENDA**  Chairman: **Prof. Dr. Tamás Masszi**  **Semmelweis University, 3rd Department of Internal Medicine, Budapest**  14:30-15:00 Registration  15.00‐15.30 **Prof. Dr. Laurent Garderet:** The importance of MRD negativity in Multiple Myeloma  **Department of hematology at Pitié Salpetrière Hospital, Paris**    15.30‐16.00 **Dr. Sandra Basic Kinda:** Mode of action of anti‐CD38: What CD38 monoclonal antibodies can achieve ‐ deep, fast and durable response  **University Hospital Centre, Zagreb**  16.00‐ 16.30 **Associate Professor Martin Mistrik, PhD:** Present and future of the frontline treatment: ASCT and treatment of NT‐eligible patients  **Hematology and Transfusiology Department of University Hospital, Bratislava**  16.30‐16.45 Coffe Break  16:45‐17:15 **Dr. Alessandra Larocca:** PI- and iMID‐based combinations with monoclonal antibodies in the treatment of MM  **Department of Hematology-Oncology of the University-Hospital Città della Salute e della Scienza, Torino**  17:15‐17:45 **Dr. Gábor Mikala:** Network Meta-analysis: PI‐ and iMID‐based combinations with new agents in RRMM  **Department of Hematology and Stem Cell Transplantation at the South-Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest**  17:45-18:15 Panel discussion and Closing | Medicinski izobraževalni forum s poudarkom na optimalnem pristopu k zdravljenju multiplega mieloma. Razprava bo zajemala zadnje mednarodne znanstvene rezultate pri zdravljenju MM ter bo omogočala izmenjavo izkušenj in dobrih praks na področju zdravljenja bolnikov z MM z inovativnimi agensi.  **PROGRAM**  Predsednik: **Prof. dr. Tamás Masszi, Univerza Semmelweis, 3. oddelek interne medicine, Budimpešta**  14:30-15:00 Prijava  15:00-15:30 **Prof dr. Laurent Garderet:** Pomen MRD negativnosti pri multiplem mielomu **Oddelek hematologije v bolnišnici Pitié Salpetrière, Paris**  15:30-16:00 **Dr. Sandra Basic Kinda:** Način delovanja anti-CD38: Kaj lahko dosežemo z monoklonskimi protitelesi CD38 – obširen, hiter in dolgotrajen odziv **Univerzitetni klinični center, Zagreb**  16:00-16:30 **Izredni profesor, dr. Martin Mistrik:** Sedanjost in prihodnost primarnega zdravljenja: ASCT in zdravljenje pacientov, primernih za NT  **Oddelek hematologije in transfuziologije v Univerzitetni bolnišnici, Bratislava**  16:30-16:45 Odmor za kavo  16:45-17:15 **Dr. Alessandra Larocca:** Kombinacije z monoklonskimi protitelesisPI in iMID osnovo pri zdravljenju MM  **Oddelek hematologije-onkologije v Univerzitetni bolnišnici Città della Salute e della Scienza, Torino**  17:15‐17:45 **Dr. Gábor Mikala:** Mrežna meta-analiza: Kombinacije z novimi agensi na osnovi PI in iMID pri RRMM  **Oddelek hematologije in transplantacije izvornih celic v Centralni bolnišnici Južna Pešta, Nacionalni institut za hematologijo in nalezljive bolezni, Budimpešta**  17:45-18:15 Panelna razprava in zaključek |

# Dan 2 – Informacije o srečanju na temo kronične limfocitne levkemije

|  |  |  |
| --- | --- | --- |
|  | **EN** | **Lokalni jezik** |
|  | **Date: 13.04.2019**  **Specialty: Hematology**  **Language: English**  **Translation languages: None**  **Start: 13.04.2019 9:00 CEST**  **Duration: 195 minutes total (breaks excluded)** | **Datum: 13. 4. 2019**  **Področje: hematologija**  **Jezik: angleščina**  **Prevod v jezike: brez**  **Začetek: 13. 4. 2019 9:00 CEST**  **Trajanje: skupno 195 minut (brez premorov)** |
| **Session title (the shorter, the better)** | The approach of chemotherapy free CLL treatment - present and future | Pristop zdravljenja KLL brez kemoterapije – sedanjost in prihodnost |
| **Short description (max. 250 characters with spaces)** | We would like to invite you to our upcoming, live and interactive medical educational forum, taking place on Saturday, 13 April 2019, broadcast from Budapest. This session will discuss optimal approach and recent advances in chronic lymphocytic leukemia. | Vabimo vas k udeležbi na prihajajočem interaktivnem medicinskem izobraževalnem forumu, katerega prenos bo v živo potekal v petek, 13. aprila 2019, iz Budimpešte. Na srečanju se bo razpravljalo o optimalnih pristopih in zadnjih dosežkih na področju zdravljenja kronične limfocitne levkemije. |
| **Description (min. 300 characters with spaces)** | The goal of the event is to provide information and new strategies for hematologists regarding treatment of chronic lympocytic leukemia.  AGENDA  Chairman: **Prof. Dr. Tamás Masszi**  **Semmelweis University, 3rd Department of Internal Medicine, Budapest**  9.00 – 9.30 **Prof. Dr. Zita Borbényi:** International CLL guideline review  **University of Szeged, 2nd Department of Internal Medicine, Szeged**  9.30 – 10. 00 **Dr. Kostas Stamatopoulos:** CLL as a paradigm for precision medicine considerations, challenges and standards  **Institute of Applied Biosciences Centre for Research and Technology Hellas, Thessaloniki**  10.00 – 10.30 **Dr. Csaba Bödör:** Modern Molecular Diagnostics of CLL- State of The Art (2019). Overview of current situation in Hungary  **Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Molecular Oncohematology Research Group, Budapest**  10.30 – 10.45 Coffee break  10.45 - 11.00 **Prof. MUDr. Michael Doubek, Ph.D.:** Local treatment decision in clinical practice of CLL in Czech Republic  **University Hospital Brno and Faculty of Medicine, CEITEC, Masaryk University, Brno**  11.00 – 11.15 **Asist. dr. Matevž Škerget:** Local treatment decision in clinical practice of CLL in Slovenia  **University Medical Centre Ljubljana, Ljubjana**  11.15 – 11.30 **Prof. Dr. Vlatko Pejsa:** Local treatment decision in clinical practice of CLL in Croatia  **Clinical Hospital Dubrava, Zagreb**  11.30 – 12.00 **Prof. Dr. John Gribben:** Therapeutic approaches to the management of high-risk CLL patients in the era of novel agents  **Barts Cancer Institute, Queen Mary University of London, London**  12.00 – 12.30 Panel discussion and Closing | Cilj dogodka je ponuditi informacije in nove strategije hematologom glede zdravljenja kronične limfocitne levkemije.  PROGRAM  Predsednik: **Prof. dr. Tamás Masszi, Univerza Semmelweis, 3. oddelek interne medicine, Budimpešta**  9:00-9:30 **Prof. dr.** **Zita Borbényi:** Pregled mednarodnih smernic KLL **Univerza v Szegedu, 2. oddelek interne medicine, Szeged**  9:30-10:00 **Dr. Kostas Stamatopoulos:** KLL kot paradigma za pomisleke v precizni medicini, izzivi in standardi **Inštitut uporabnih bioznanosti Center za raziskave in tehnologijo Hellas, Solun**  10:00 – 10:30 **Dr. Csaba Bödör:** Sodobna molekularna diagnostika KLL - najnovejša spoznanja (2019). Pregled trenutnega stanja na Madžarskem **Univerza Semmelweis, 1. oddelek patologije in eksperimentalnih raziskav rakavih obolenj, Molekularna onkohematološka raziskovalna skupina, Budimpešta**  10:30-10:45 Odmor za kavo  10:45 - 11:00 **Prof. dr. Michael Doubek, dr. med.:** Lokalne odločitve glede zdravljenja v klinični praksi pri KLL na Češkem **Univerzitetna bolnišnica Brno in Fakulteta za medicino, CEITEC, Univerza Masaryk, Brno**  11:00 – 11:15 **Asist. dr. Matevž Škerget:** Lokalne odločitve glede zdravljenja v klinični praksi pri KLL v Sloveniji  **Univerzitetni klinični center Ljubljana, Ljubljana**  11:15 – 11:30 **Prof. dr. Vlatko Pejsa:** Lokalne odločitve glede zdravljenja v klinični praksi pri KLL na Hrvaškem **Bolnišnica Dubrava, Zagreb**  11:30 – 12:00 **Prof. dr. John Gribben:** Terapevtski pristopi k ravnanju z rizičnimi KLL pacienti v dobi novih agensov  **Inštitut za rakava obolenja Barts, Univerza Queen Mary, London**  12:00-12:30 Panelna razprava in zaključek |

# Informacije o nastopajočih

|  |  |  |  |
| --- | --- | --- | --- |
| 1. **NASTOPAJOČI** | **Naziv + ime + priimek** | Prof. dr. Tamás Masszi | Prof. dr. Tamás Masszi |
| **Država** | Hungary | Madžarska |
| **Ustanova** | 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary | 3. oddelek interne medicine, Univerza Semmelweis, Budimpešta, Madžarska |
| **Opis/biografija** | Tamás Masszi is currently Vice-Dean of the Faculty of Medicine, Semmelweis University, since 2012, where he also serves as Director of the 3rd Department of Internal Medicine.  Professor Masszi received his medical degree from Semmelweis University Medical School in 1983. In 1992 he had a scholarship in Paris for clinical training at the Department of Bone Marrow Transplantation of Hopital St Louis led by Eliane Gluckman.  In 1993 he became a Consultant Haematologist at the Department of Haematology and Bone Marrow Transplantation, St. László Hospital, Budapest, where he was appointed Head of the Bone Marrow Transplantation Unit in 1997. Professor Masszi became Head of the Department of Haematology and Stem Cell Transplantation at St. István and St. László Hospitals in 2007 and served in the position until June 2016.  Professor Masszi is a member of several scientific societies and was the President of the Hungarian Society of Haematology and Blood Transfusion from 2007 to 2011. He served as Chair of the Education Committee for the European Group for Blood and Marrow Transplantation between 2003 and 2012. Since 2003 he is the chair of the National Board for Haemopoietic Stem Cell Transplantation.  He has authored or co-authored more than 140 papers in the field of haematological malignancies. | Tamás Masszi je od 2012 poddekan Fakultete za medicino, Univerza Semmelweis, kjer deluje tudi kot direktor 3. oddelek interne medicine.  Profesor Masszi je leta 1983 diplomiral s področja medicine na Univerzi Semmelweis. Leta 1992 je odšel v Pariz na klinično izobraževanje na Oddelku transplantacij kostnega mozga v Bolnišnici St. Louis, pod vodstvom Eliane Gluckman.  Leta 1993 je postal hematolog svetovalec na Oddelku hematologije in transplantacij kostnega mozga v Bolnišnici St. László, Budimpešta, kjer je leta 1997 prevzel vodenje Enote za transplantacije kostnega mozga. Profesor Masszi je leta 2007 postal vodja Oddelka hematologije in transplantacij izvornih celic v bolnišnicah St. István in St. László, kjer je deloval do junija 2016.  Profesor Masszi je član več znanstvenih društev in je med letoma 2007 in 2011 predsedoval Madžarskemu društvu za hematologijo in transfuzijo krvi. Med letoma 2003 in 2012 je načeloval Izobraževalnemu odboru za transplantacije krvi in kostnega mozga. Od leta 2003 je predsednik Nacionalnega sveta za hemopoetske transplantacije izvornih celic.  Je avtor oziroma soavtor več kot 140 člankov s področja hematološkoih malignosti. |
|  | |  |  |
| **SPEAKER 2** | **Naziv + ime + priimek** | Prof Dr Laurent Garderet | Prof. dr. Laurent Garderet |
| **Država** | France | Francija |
| **Ustanova** | Pitié Salpetriére Hospital in Paris, France. | Bolnišnica Pitié Salpetriére v Parizu, Francija |
| **Opis/biografija** | Dr Laurent Garderet is a French hematologist working in the department of hematology at Pitié Salpetrière Hospital in Paris, France. He did his medical studies as well as his training in Paris. He did a post-doctoral internship in the M.D Anderson Cancer Center in Houston. His main interests focus on myeloma treatment and biology. He is a board member of the IFM and past chairman of the Plasma Cell Disorder subcommittee of the EBMT Chronic Malignancies Working Party. | Dr. Laurent Garderet je francoski hematolog, ki dela na Oddelku hematologije v Bolnišnici Pitié Salpetriére v Parizu, Francija. Študij medicine in prakso je opravil v Parizu. Podoktorsko pripravništvo je opravil v ustanovi M.D. Anderson Cancer Center v Houstonu. Ukvarja se predvsem z zdravljenjem in biologijo mieloma. Je član sveta IFM in bivši predsednik Pododbora za plazmatske celične bolezni, v okviru Delovne skupine EBMT za kronične malignosti. |
|  | |  |  |
| **SPEAKER  3** | **Naziv + ime + priimek** | Sandra Bašić Kinda, dr.med. | Sandra Bašić Kinda, dr. med. |
| **Država** | Croatia | Hrvaška |
| **Ustanova** | Sandra Bašić Kinda, dr.med. | Sandra Bašić Kinda, dr. med. |
| **Opis/biografija** | Dr. Bašić-Kinda graduated from the Medical School, University of Rijeka, Croatia. She finished her internship, residency in internal medicine in GH Zadar and fellowship in hematology at the University Hospital Centre Zagreb. The primary scientific interest of Dr. Bašić-Kinda is clinical research in CLL, myeloma and lymphoma. She is a member of EORTC Lymphoma Group; member of the European Mantle Cell Lymphoma Network, chairman of the Myeloma subcommittee of CroHem, the Croatian Cooperative Group for Hematologic Diseases; member and secretary of the Steering Committee of the Croatian Hematological Society; member of ERIC (European Research Initiative on CLL); member of the Steering Committee of charitable Croatian Leukaemia - Lymphoma Association | Dr. Bašić-Kinda je diplomirala na Medicinski šoli Univerze na Reki, Hrvaška. Pripravništvo s področja interne medicine je zaključila v Splošni bolnišnici v Zadru, specializacijo iz hematologije pa v Univerzitetnem kliničnem centru Zagreb. Dr. Bašić-Kinda se v svojih znanstvenih prizadevanjih osredotoča na klinične raziskave KLL, mieloma in limfoma. Je članica EORTC skupine za limfom; članica Evropske mreže za limfom plaščnih celic, predsednica Pododbora za mielom v okviru CroHem – hrvaške kooperativne skupine za hematološke bolezni; članica in sekretarka pripravljalnega odbora Hrvaškega hematološkega društva; članica ERIC (Evropska raziskovalna pobuda glede KLL); članica pripravljalnega odbora dobrodelnega Hrvaškega združenja za levkemijo in limfom. |
|  | |  |  |
| **SPEAKER  4** | **Naziv + ime + priimek** | Doc. MUDr. Martin Mistrík, PhD. | Doc. dr. Martin Mistrík, dr. med. |
| **Država** | Slovakia | Slovaška |
| **Ustanova** | Head of the Clinic of Hematology and Transfusiology, LF UK, SZU and UNB, St. Cyril and Method | Vodja Klinike za hematologijo in transfuziologijo, LF UK, SZU in UNB, Sv. Ciril in Metod |
| **Opis/biografija** | Doc. MUDr. Martin Mistrík, PhD is Head of the Hematology and Transfusiology Department at the Clinic of Hematology and Transfusiology of the University Hospital Bratislava, Slovakia.   He is the main expert of the Ministry of Health of the Slovak Republic for hematology since 2007 and also for hematopoietic stem cell transplantation since 2012.  He is author and co-author of several articles published in peer-reviewed journals, mainly in the field of ASCT. He works also as reviewer for several journals. He is member of EBMT,LG-EORTC, EHA and ASH | Doc. dr. Martin Mistrík, dr. med., je vodja Oddelka hematologije in transfuziologije na Kliniki za hematologijo in transfuziologijo v okviru Univerzitetne bolnišnice Bratislava, Slovaška.  Od leta 2007 je glavni strokovnjak za hematologijo na Ministrstvu za zdravje Republike Slovaške, kot tudi za transplantacije hematopoetskih izvornih celic od leta 2012.  Je avtor in soavtor več člankov v strokovnih revijah, pretežno na področju ASCT. Deluje tudi kot recenzent mnogih revij. Je član EBMT, LG-EORTC, EHA in ASH. |
|  | |  |  |
| **SPEAKER  5** | **Naziv + ime + priimek** | Dr Alessandra Larocca | Dr. Alessandra Larocca |
| **Država** | Italy | Italija |
| **Ustanova** | University Hospital Città della Salute e della Scienza, Torino, Italy. | Univerzitetna bolnišnica Città della Salute e della Scienza, Torino, Italija |
| **Opis/biografija** | Alessandra Larocca, MD, PhD is Assistant Professor of the Division of Hematology at the Department of Hematology-Oncology of the University-Hospital Città della Salute e della Scienza, Torino, Italy. She received her medical degree from University of Milano, where she also served her residency in Hematology. She got her PhD in Pathology and Experimental Oncology at the University of Torino in 2014.   Her research interests includes multiple myeloma and associated disorders, and in particular the treatment of elderly and frail patients, and the assessment of frailty. | Dr. Alessandra Larocca, dr. med., je docentka na Sektorju hematologije na Oddelku hematologije-onkologije v okviru Univerzitetne bolnišnice Città della Salute e della Scienza, Torino, Italija. Iz medicine je diplomirala na Univerzi v Milanu, kjer je opravila tudi specializacijo iz hematologije. Leta 2014 je na Univerzi v Torinu doktorirala iz patologije in eksperimentalne onkologije.  Njeno znanstveno delo zajema multipli mielom in sorodne bolezni, s poudarkom na zdravljenju starejših in slabotnih pacientov ter na ocenjevanju slabotnosti. |
|  | |  |  |
| **SPEAKER  6** | **Naziv + ime + priimek** | Gábor Mikala MD, PhD | Dr. Gábor Mikala, dr. med |
| **Država** | Hungary | Madžarska |
| **Ustanova** | South-Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary | Centralna bolnišnici Južna Pešta, Nacionalni inštitut za hematologijo in nalezljive bolezni, Budimpešta, Madžarska |
| **Opis/biografija** | Gabor Mikala is Division Head for Myeloma and Lymphoma Therapy at the Department of Hematology and Stem Cell Transplantation at the South-Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary. He received his medical degree at Semmelweis University, Budapest. Postdoctoral research was carried out at the University of Cincinnati, Institute of Molecular Pharmacology and Biophysics. Awarded by PhD in Molecular Physiology by Semmelweis University in 1999.   His main interest is multiple myeloma and Waldenström’s disease.  He is an author and co-author of sevaral papers on the field of multiple myeloma, including Hungarian treatment guidelines. He represents Hungary at the International Myeloma Working Group | Gábor Mikala je vodja Sektorja zdravljenja mieloma in limfoma na Oddelku hematologije in transplantacije izvornih celic v Centralni bolnišnici Južna Pešta, Nacionalni institut za hematologijo in nalezljive bolezni, Budimpešta, Madžarska. Iz medicine je diplomiral na Univerzi Semmelweis, Budimpešta. Podoktorske raziskave je opravil na Univerzi v Cincinnatiju, Inštitut za molekularno farmakologijo in biofiziko. Leta 1999 je na Univerzi Semmelweis prejel doktorat s področja molekularne fiziologije.  Osredotoča se na raziskave multiplega mieloma in Waldenströmove bolezni.  Je avtor in soavtor več člankov s področja multiplega mieloma, tudi glede smernic zdravljenja na Madžarskem. Na Mednarodni delovni skupini za mielom zastopa Madžarsko. |
|  | |  |  |
| **SPEAKER  7** | **Naziv + ime + priimek** | Prof. Dr. Zita Borbényi | Prof. dr. Zita Borbényi |
| **Država** | Hungary | Madžarska |
| **Ustanova** | 2nd Department of Internal Medicine and Cardiology Centre, University of Szeged, Szeged, Hungary | 2. oddelek Centra za interno medicino in kardiologijo, Univerza v Szegedu, Szeged, Madžarska |
| **Opis/biografija** | She was graduated at Medical School of Szeged, started her work as a resident of internal medicine. After her qualification as an internist and hematologist she continued her work at the 2nd Department of Internal Medicine, University of Szeged. Her positions at the department: Assistant, Lecturer, Senior Lecturer and Professor of Hematology. She is the Head of the Haematology Department at the University of Szeged since 2007. She had several international scholarships in clinical and scientific field in England, Germany, Switzerland and Austria between 1982 and 2003. Regarding gradual education, she is teaching medical students since 1975. Considering the postgradual education, she is lecturer of initiative courses for special examination for clinical transfusiologist, clinical hematologist. She coordinates the work for Ph.D. students and she is the Head of the Gremium of Haematology and Transfusiology at the University of Szeged.  She is a member of American Society of Haematology, International Union Against Cancer, International Society of Haematology, European Haematological Association; Hungarian Cancer Society, Hungarian Society of Internal Medicine, and the Hungarian Society of Haematology and Blood Transfusion.    Her main interest is the treatment of lymphoproliferative disorders and acute leukemias. | Zaključila je študij na Medicinski šoli v Szegedu in začela delo na področju interne medicine. Po specializaciji iz internistike in hematologije je nadaljevala z delom na 2. oddelku interne medicine, Univerza v Szegedu. Njena mesta v oddelku: docentka, predavateljica, višja predavateljica in profesorica hematologije. Od leta 2007 je vodja Oddelka hematologije na Univerzi v Szegedu. Med letoma 1982 in 2003 je bila prejemnica več mednarodnih štipendij s kliničnih in znanstvenih področij v Angliji, Nemčiji, Švici in Avstriji. Dodiplomske študente medicine poučuje od leta 1975. Pri podiplomskem študiju je predavateljica začetnih predmetov na področju specializacije za kliničnega transfuziologa in kliničnega hematologa. Usklajuje delo doktorskih študentov in je vodja Odbora hematologije in transfuziologije na Univerzi v Szegedu.  Je članica Ameriškega hematološkega društva, Mednarodne zveze proti raku, Mednarodnega hematološkega društva, Evropskega hematološkega združenja, Madžarskega društva za rakava obolenja, Madžarskega društva za interno medicino ter Madžarskega društva za hematološko in krvno transfuzijo.  Pri delu je osredotočena na zdravljenje limfoproliferativnih bolezni in akutnih levkemij. |
|  | |  |  |
| **SPEAKER  8** | **Naziv + ime + priimek** | Kostas Stamatopoulos, MD, PhD | Dr. Kostas Stamatopoulos, dr. med. |
| **Država** | Greece | Grčija |
| **Ustanova** | CERTH, Centre for Research and Technology Hellas | Thessaloniki | Greece | CERTH, Center za raziskave in tehnologijo Hellas, Solun, Grčija |
| **Opis/biografija** | Kostas Stamatopoulos, MD, PhD, is a specialist in Hematology, Director of the Institute of Applied Biosciences at CERTH, the Center for Research and Technology Hellas, Thessaloniki, Greece. He also holds the positions of Visiting Professor at the Karolinska Institute, Stockholm, Sweden; and, Research Collaborator of the Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. Dr Stamatopoulos is the coordinator of the Greek Precision Medicine Network in Oncology; Board member of ERIC, the European Research Initiative on CLL; founding member of the IMGT CLL-DB initiative and the IgCLL group, both operating under the auspices of ERIC; Board member of the Splenic Lymphoma Group; member of the Steering Group of the Euroclonality-NGS Consortium. Dr Stamatopoulos is a member of the Hellenic Society of Haematology, the European Haematology Association, the American Society of Hematology, amongst others, and has served in different committees of these organizations. His research interests include: precision medicine in cancer; immunobiology of lymphoid malignancies; and, patient empowerment in care. | Dr. Kostas Stamatopoulos, dr. med., je specialist hematologije, direktor Inštituta uporabnih bioznanosti na CERTH, Centru za raziskave in tehnologijo Hellas, Solun, Grčija. Deluje tudi kot gostujoči profesor na Karolinska inštitutu, Stockholm, Švedska; in kot raziskovalni sodelavec Oddelka hematologije in HCT enote v Bolnišnici G. Papanicolaou, Solun, Grčija. Dr. Stamatopoulos je koordinator Grške mreže za precizno medicino na področju onkologije; član sveta ERIC, Evropske raziskovalne pobude glede KLL; ustanovni član pobude IMGT CLL-DB ter skupine IgCLL, obe pod okriljem ERIC; član sveta Skupine za splenični limfom; član pripravljalne skupine Konzorcija Euroclonality-NGS. Dr. Stamatopoulos je med drugim član Grškega hematološkega društva, Evropskega hematološkega združenja in Ameriškega hematološkega društva, kjer je deloval v različnih odborih teh organizacij. Raziskuje na področjih: precizna medicina na področju rakavih obolenj; imunobiologija limfoidnih malignosti; ter samostojnost pacientov na področju nege. |
|  | |  |  |
| **SPEAKER  9** | **Naziv + ime + priimek** | Csaba Bödör, PhD | Dr. Csaba Bödör |
| **Država** | Hungary | Madžarska |
| **Ustanova** | 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary | 1. oddelek patologije in eksperimentalnih raziskav na področju rakavih obolenj, Univerza Semmelweis, Budimpešta, Madžarska |
| **Opis/biografija** | Csaba Bödör obtained his PhD degree from molecular oncology at Semmelweis University in 2008. He developed interest in molecular pathogenesis of hematological malignancies. He spent three years in Barts Cancer Institute (London, UK) with a postdoctoral research fellowship from the European Hematology Association (EHA). After his return to Hungary he developed a research program on genomic and epigenetic background of B-cell lymphomas and familial myeloid malignancies.   Currently, he is the head of the molecular diagnostics unit and the molecular oncohematology research group at the Department of Pathology and Experimental Cancer Research, Semmelweis University | Csaba Bödör je leta 2008 doktoriral iz molekularne onkologije na Univerzi Semmelweis. Usmeril se je na področje molekularne patogeneze hematoloških malignosti. Tri leta je preživel kot podoktorski raziskovalec na Inštitutu za rakava obolenja Barts (London, VB), pod okriljem Evropskega hematološkega združenja (EHA). Po vrnitvi na Madžarsko je razvil raziskovalni program o genomskem in epigenetskem ozadju limfomov B-celic ter družinskih mieloidnih malignosti.  Trenutno je vodja enote za molekularno diagnostiko ter raziskovalne skupine za molekularno onkohematologijo na Oddelku patologije in eksperimentalnih raziskav rakavih obolenj, Univerza Semmelweis. |
|  | |  |  |
| **SPEAKER  10** | **Naziv + ime + priimek** | Prof. MUDr. Michael Doubek, Ph.D | Prof. dr. Michael Doubek, dr. med. |
| **Država** | Czech Republic | Češka |
| **Ustanova** | Department of Internal Medicine, Hematology and Oncology, University Hospital Brno | Oddelek interne medicine, hematologije in onkologije, Univerzitetna bolnišnica Brno |
| **Opis/biografija** | Michael Doubek, MD, Ph.D. is Professor at the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno. He received his medical degree from Masaryk University in Brno, where he graduated in 1996. There he also got his Ph.D. in 2003. He is Professor of Oncology from 2011. He received certificates in Hematology and Transfusion Medicine, Internal Medicine and Medical Genetics.   Prof. Doubek is actively interested and works in a field of acute and chronic leukemia, aplastic anemia, myeloproliferative disorders, immune thrombocytopenia, flow cytometry in hematology (minimal residual disease detection in lymphoid malignancies and acute leukemias), NGS and immunophenotyping in hemato-oncology.    He is author or co-author of more than 200 publications, with more than 100 published in journals with impact factor, author or co-author of 7 monographs (3 international) and more than 50 chapters in medical textbooks.      He is principal investigator or co-investigator of several grants, author or coordinator of several clinical trials and participant in more than 30 phase I-III clinical trials. He is member of international groups GMALL, EHA, EBMT, EWALL, and national study groups CELL. Since 2018 he is head of Czech Study Group of Chronic Lymphocytic Leukemia. | Dr. Michael Doubek, dr. med., je profesor na Oddelku interne medicine, hematologije in onkologije, Univerzitetna bolnišnica Brno. Iz medicine je diplomiral leta 1996 na Univerzi Masaryk v Brnu. Tam je tudi doktoriral leta 2003. Od leta 2011 je profesor onkologije. Je prejemnik certifikatov s področij hematologije in transfuzijske medicine, interne medicine in medicinske genetike.  Prof. Doubek je aktiven na področju akutne in kronične levkemije, aplastične anemije, mieloproliferativnih bolezni, imunske trombocitopenije, pretočne citometrije v hematologiji (detekcija minimalnega preostanka bolezni pri limfoidnih malignostih in akutnih levkemijah), NGS in imunofenotipiziranja v hematoonkologiji.  Je avtor ali soavtor več kot 200 publikacij, z več kot 100 objavami v odmevnih revijah, avtor ali soavtor 7 monografij (3 mednarodnih) ter več kot 50 poglavij v učbenikih medicine.  Je glavni raziskovalec ali soraziskovalec v več raziskavah, avtor ali koordinator mnogih kliničnih preizkusov ter udeleženec v več kot 30 kliničnih preizkusih I-III faze. Je član mednarodnih skupin GMALL, EHA, EBMT, EWALL in nacionalnih študijskih skupin CELL. Od leta 2018 je vodja Češke študijske skupine za kronično limfocitno levkemijo |
|  | |  |  |
| **SPEAKER  11** | **Naziv + ime + priimek** | asist.dr. Matevž Škerget, dr. med. | asist. dr. Matevž Škerget, dr. med. |
| **Država** | Slovenia | Slovenija |
| **Ustanova** | Clinical Department of Hematology at the University Medical Centre Ljubljana | Klinični oddelek hematologije v Univerzitetnem kliničnem centru Ljubljana |
| **Opis/biografija** | After graduating at the Faculty of Medicine in 2006, he began his internal medicine specialization at the Clinical Department of Hematology at the University Medical Centre Ljubljana. Specialization was completed in 2013, and in 2016 he obtained his PhD at the Faculty of Medicine, University of Ljubljana. He worked as a chief researcher and co-researcher on several international and national clinical studies in the field of chronic lymphocytic leukemia treatment, multiple myeloma treatment, treatment of anemia in cancer patients, and other treatments. He is the author and co-author of several contributions published at international and national congresses, as well as professional and popular articles concerning the field of hematology in influential Slovenian and foreign journals. | Po zaključku študija na Medicinski fakulteti leta 2006 je pričel s specializacijo na področju interne medicine na Kliničnem oddelku hematologije v Univerzitetnem kliničnem centru Ljubljana. S specializacijo je zaključil leta 2013 in nato leta 2016 doktoriral na Medicinski fakulteti Univerze v Ljubljani. Bil je glavni raziskovalec in soraziskovalec pri več mednarodnih in domačih kliničnih raziskavah s področja zdravljenja kronične limfocitne levkemije, multiplega mieloma, anemije pri rakavih bolnikih ter drugih zdravljenj. Je avtor ali soavtor prispevkov, objavljenih na mednarodnih in domačih kongresih, kot tudi strokovnih in poljudnih člankov s področja hematologije v odmevnih slovenskih in tujih revijah. |
|  | |  |  |
| **SPEAKER  12** | **Naziv + ime + priimek** | Prof. Vlatko Pejša, MD, PhD | Prof. dr. Vlatko Pejša, dr. med. |
| **Država** | Croatia | Hrvaška |
| **Ustanova** | University Hospital Dubrava, Zagreb | Univerzitetna bolnišnica Dubrava, Zagreb |
| **Opis/biografija** | Prof. Vlatko Pejša MD, PhD, graduated from Medical School University of Zagreb, Croatia. He finished his residency in Internal medicine and works as Hematology consultant. He is Professor at School of Medicine, University of Zagreb. For more than 20 years he has been head of Hematology Department at University Hospital Dubrava, Zagreb, where he established stem cell transplantation program.  The primary scientific interest of Prof. Pejša is basic and clinical research in CLL and lymphoma. He is active member of EBMT; EORTC and CroHem; the Croatian Cooperative Group for Hematologic Diseases. He is also leader of the working group for CLL of CroHem, member of the Steering Committee of the Croatian Hematologic Society and member of the Steering Committee of charitable Croatian Leukaemia - Lymphoma Association. | Prof. dr. Vlatko Pejša, dr. med., je diplomiral na Medicinski šoli Univerze v Zagrebu, Hrvaška. Opravil je specializacijo na področju interne medicine in dela kot hematološki svetovalec. Je profesor na Medicinski šoli Univerze v Zagrebu. Že več kot 20 let je vodja Oddelka hematologije v Univerzitetni bolnišnici Dubrava, Zagreb, kjer je vzpostavil program transplantacije izvornih celic.  Glavni znanstveni interes prof. Pejše so osnovne in klinične raziskave KLL in limfoma. Je aktiven član EBMT, EORTC in CroHem, hrvaške kooperativne skupine za hematološke bolezni. Je tudi vodja delovne skupine za KLL pri CroHem, član pripravljalnega odbora Hrvaškega hematološkega društva ter član pripravljalnega odbora dobrodelnega Hrvaškega združenja za levkemijo in limfom. |
|  | |  |  |
| **SPEAKER  13** | **Naziv + ime + priimek** | Professor John G. Gribben  MD, DSc, FRCP, FRCPath, FMedSci  Professor of Medical Oncology | Prof. dr. John G. Gribben, dr. med., FRCP, FRCPath, FmedSci  Profesor medicinske onkologije |
| **Država** | UK | VB |
| **Ustanova** | Barts Cancer Institute  Queen Mary, University of London | Inštitut za rakava obolenja Barts  Univerza Queen Mary, London |
| **Opis/biografija** | Professor John Gribben graduated in medicine from the University of Glasgow in 1980. He was a doctoral fellow at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School. He remained on the faculty for at Harvard Medical School 17 years before returning to the UK in 2005. He specializes in hematological cancers including lymphomas, leukemias and bone marrow transplantation and immunotherapy approaches including CAR-T cells.  He holds the Hamilton Fairley Chair of Medical Oncology at Barts and the London School of Medicine, Queen Mary, University of London and his NHS post is as Honorary Consultant Medical Oncologist Barts and The London NHS Trust.  He is the author of more than 500 articles and chapters in peer-reviewed publications and has a global reputation for his work in researching new drugs and forms of cancer treatment and the tole of immunotherapy in cancer. He has grant funding from The National Cancer Institute, Cancer Research UK, Wellcome Trust and the Medical Research Council for pioneering studies in leukaemia and lymphoma.  He takes up his role as President of the European Hematology Association (EHA) for 2 years from June 2019 is currently serves on the EHA Executive Board. He is Chair of the international workshop for non-Hodgkin’s lymphoma (iwNHL) and co-chair of the international workshop for CAR T cells (iwCART). He was an Editor of Blood from 2007-2014. He is a on the Board of Trustees of the London Clinic. | Profesor John Gribben je diplomiral iz medicine na Univerzi v Glasgowu leta 1980. Doktorat je opravljal na Univerzitetnem kolidžu v Londonu in se izpopolnjeval na področju medicinske onkologije na Inštitutu za rakava obolenja Dana Faber, Medicinska šola Harvard. Na Medicinski šoli Harvard je ostal 17 let, preden se je leta 2005 vrnil v VB. Specializiral se je za hematološka rakava obolenja, vključno z limfomi, levkemijami, transplantacijami kostnega mozga ter imunoterapevtskimi pristopi, ki vključujejo celice CAR-T.  Na inštitutu Barts in Londonski medicinski šoli, Univerza Queen Mary v Londonu, je vodja Oddelka medicinske onkologije. Deluje tudi kot častni svetovalec na področju medicinske onkologije v okviru sistema Nacionalnih zdravstvenih storitev.  Je avtor več kot 500 člankov in poglavij v strokovnih publikacijah. Po vsem svetu je znan po svojem delu na področju raziskave novih zdravil in oblik zdravljenja rakavih obolenj ter vloge imunoterapije pri rakavih obolenjih. Sredstva za raziskave je dobil od Nacionalnega inštituta za rakava obolenja, sklada Wellcome za raziskave rakavih obolenj ter Medicinskega raziskovalnega sveta za nove raziskave levkemije in limfoma.  Od junija 2019 je za dve leti prevzel predsedovanje Evropskemu hematološkemu združenju (EHA) in trenutno opravlja delo v upravi EHA. Je predsednik mednarodne delavnice na področju ne-Hodgkinovega limfoma (iwNHL) in sopredsednik mednarodne delavnice na področju celic CAR-T (iwCART). Med letoma 2007 in 2014 je bil urednik publikacije Blood. Je član kuratorija Londonske klinike. |